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Effects of hypoxia on renal growth factor expression in the rat kidney.
There is accumulating evidence from in vitro studies suggesting that the
genes of endothelin-1, PDGF, and VEGF are, like the erythropoietin
gene, regulated by oxygen tension and by divalent cations. Hypoxia-
induced stimulation of, such as endothelin-1, PDGF or VEGF might be
involved in the pathogenesis of acute or chronic renal failure, and in renal
"infiammatoiy" diseases (glomerulonephritis, vasculitis, allograft rejec-
tion). Hypoxia (8% 02) for six hours caused a 55-fold/i .6-fold increase of
renal erythropoietin/endothelin- 1 gene expression, whereas endothelin-3,
PDGF-A, PDGF-B, and VEGF gene expression was unchanged. Carbon
monoxide (0.1%) treatment for six hours stimulated renal erythropoietin
gene expression 140-fold; however, endothelin-1, endothelin-3, PDGF-A,
PDGF-B, and VEGF gene expression was not affected. Finally, cobalt
treatment (60 mg/kg C0C12) increased only renal erythropoietin/PDGF-B
gene expression 5-fold/1.65-fold. These findings suggest that hypoxia is a
rather weak stimulus for renal endothelin-1 gene expression, and that
renal PDGF and VEGF gene expression in vivo is not sensitive to tissue
hypoxia, in contrast to cell culture experiments. The in vivo regulation of
endothelin-l, PDGF, and VEGF differs substantially from that of eryth-
ropoietin, suggesting that the basic gene regulatory mechanisms may not
be the same.
A series of cell culture studies have suggested that hypoxia
induces the gene expression of endothelin-1, PDGF-B, and VEGF
in a manner similar to hypoxia-induced erythropoietin gene
expression [1—7]. Recent in vivo studies have been somewhat more
contradictory. Endothelin-1 has been shown to cause hypoxia-
induced pulmonary hypertension via activation of the endothelin
ETA-receptor and to be stimulated by renal hypoperfusion in
unilateral renal artery stenosis [8, 9]. In hypoxic rats only a
moderate increase by about 30% or 60% has been shown for
PDGF-B or PDGF-A mRNA in pulmonary tissue [10]. With
regard to VEGF gene expression, Minchenko et a! [11] have
suggested a stimulation by hypoxia in only certain organs.
Since erythropoietin gene expression in kidneys in vivo is
stimulated more than 100-fold by hypoxia and since it has been
suggested that the mode of stimulation of different growth factors
and endothelins by hypoxia is the same than that of erythropoietin
[5, 11—161, it was of interest to us to study whether the in vivo gene
expression of endothelin-1 and -3, PDGF-A and -B, VEGF
changes in parallel to erythropoietin in kidneys of rats subjected
to different hypoxic stimuli.
Hypoxia-induced stimulation of the secretion of endothelin-1
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might be involved in acute renal failure, progression of chronic
renal failure and of other renal diseases, such as glomerulone-
phritis [17—23], whereas hypoxia-induced stimulation of PDGF
release has been related to renal allograft rejection, renal fibrosis,
and diabetic and hypertensive nephropathies [23—29]. Finally
hypoxia-induced secretion of VEGF might be involved in vascu-
larization of renal cell carcinomas and re-establishment of vascu-
lar integrity in renal allograft rejection or vasculitis [30, 31].
Methods
Animal experiments
All animal experiments were conducted according to the NIH
guideline, Guide for the Care and Use of Laboratoiy Animals, and
the German Law on the Protection of Animals. Male Sprague-
Dawley rats (200 to 250 g), having free access to food and water
were used for all experiments. Four groups of animals were
studied: (1.) untreated controls; (2.) hypoxia for six hours in a
gas-tight box continuously gassed with 8% 02/92% N2; (3.) carbon
monoxide for six hours in a gas-tight box continuously gassed with
0.1% carbon monoxide in room air; (4.) cobalt treatment six hours
before sacrifice using CoCI2 (12 and 60 mg/kg s.c.). At the end of
the experiments the animals were killed by decapitation and blood
was collected from the carotid arteries for determination of
hematocrit. The kidneys were rapidly removed, weighed, cut into
halves and frozen in liquid nitrogen. The kidneys were stored at
—80°C until isolation of total RNA.
Isolation of RAT,4
Total RNA was isolated according to the protocol of Chom-
czynski and Sacchi [14]. The organs were homogenized in 10 ml
solution D [guanidine thiocyanate (4 mM) containing 0.5% N-
lauryl-sarcosinate, 10 mM EDTA, 25 m sodium citrate, 700 mM
J3-mercaptoethanolj with a polytron homogenizer. Sequentially, 1
ml sodium acetate (2 mivi, pH 4), 10 ml phenol (water saturated)
and 2 ml chloroform were added to the homogenate, with
thorough mixing after the addition of each reagent. After cooling
on ice for 15 minutes, the samples were centrifuged at 4°C (15
mm, 10,000 g) and the supernatant was precipitated with an equal
volume of isopropanol at —20°C for one hour. After centrifuga-
tion, RNA pellets were resuspended in 0.5 ml solution D, again
precipitated with an equal volume of isopropanol at —20°C, and
finally dissolved in DEPC-treated (that is, diethylpyrocarbonate)
water and stored at —80°C.
444
Kramer et al: Hypoxia and renal growth factor expression 445
Determination of e.'ythropoietin, endothelin, PDGF, and VEGF
mRNA
mRNAs of erythropoietin, endothelin-1 and endothelin-3,
PDGF-A and PDGF-B chain, and VEGF were determined by
RNase protection as described in detail previously [13—161.
Statistics
Levels of significance were estimated by analysis of variance
(ANOVA) followed by Student's unpaired t-test. P < 0.05 was
considered significant.
Results
Basal gene expression of erythropoietin, endothelin-1, endothe-
lin-3, PDGF-A, PDGF-B, VEGF in the kidney was rather low for
erythropoietin (1 cpm/xg RNA), endothelin-1 (1.5 cpm/1cxg RNA),
endothelin-3 (3.0 cpm4tg RNA), but considerably higher for
PDGF-A (22 cpm/g RNA), PDGF-B (17 cpm!jxg RNA), VEGF-
188 (20 cpm/jxg RNA), VEGF-164 (30 cpm/xg RNA), and
VEGF-120 (5 cpm/jxg RNA) (Fig. 1). Endothelin-2 mRNA was
not detectable in the kidneys.
Erythropoietin gene expression was increased about 140-fold
with carbon monoxide (P < 0.05), about 55-fold during hypoxia
(P < 0.05), and about fivefold with cobalt treatment (P < 0.05)
(Fig. 2). Endothelin-1 gene expression was increased by about
1.6-fold during hypoxia (P < 0.05), about 1.3-fold with carbon
monoxide (NS), and unchanged with cobalt treatment, whereas
endothelin-3 gene expression was virtually unchanged with carbon
monoxide, hypoxia, and cobalt treatment (Fig. 3). PDGF-A and
PDGF-B chain gene expression was unchanged during hypoxia
and carbon monoxide (Fig. 3). In contrast, cobalt at the higher
dose (60 mg/kg) increased PDGF-A and PDGF-B gene expres-
sion by about 1.35-fold (NS) and 1.65-fold (P < 0.05) (Fig. 3).
VEGF gene expression was unchanged with carbon monoxide,
during hypoxia, and cobalt treatment (Fig. 2). Since none of the
hypoxic stimuli changed the proportion of these subtypes, that is,
alternative splicing of VEGF [188, 164, 120], VEGF is given as
total abundance of whole VEGF mRNAs (corrected for the
different lengths of the protected fragments) in Figure 2 [16].
Discussion
Endothelins have been implicated in the pathogenesis of, such
as arterial hypertension, malignant hypertension, chronic renal
failure and acute renal failure [17—19]. In the kidney endothelins
reduce renal blood flow and glomerular filtration rate due to
vasocoristriction of both afferent and efferent arterioles, but also
of arcuate and interlobar arteries [17, 19, 20]. A role of hypoxia-
induced stimulation of endothelin release, causing acute renal
failure is conceivable, since stimulation of endothelin release and
up-regulation of renal endothelin receptors has been demon-
strated in different experimental models (nephrotoxic, ischemic)
of acute renal failure [17—19]. In addition, treatment with endo-
thelin antibodies or with endothelin receptor antagonists has been
shown to ameliorate the course of acute renal failure [17—19],
Furthermore, there is evidence for an increase of renal vascular
resistance during hypoxia that could involve the action of endo-
thelins [21]. However in acute renal impairment caused by
hemorrhage, treatment with an endothelin ETA receptor antago-
nist was not beneficial (Kramer BK et al, unpublished observa-
tion). Long-term moderate hypoxemia in chronic renal failure
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Fig. 1. Abundance of renal gene expression of (A,) eiythropoietin (EPO),
VEGF-188, VEGF-164, VEGF-120, and (B) PDGF-A, PDGF-B, endothe-
lin-1 (ET-l), and endothelin-3 (ET-3) given as cpm/1g of total RNA. Data
are means SEM of 6 animals in each group.
might contribute to the increased plasma levels of endothelin-l in
chronic renal failure and to the deterioration of renal function.
Although systematic studies of the influence of hypoxia on
endothelins in chronic renal failure are lacking, beneficial effects
of endothelin receptor antagonists in the course of this disease
warrant further study of the above hypothesis [17—19, 22]. Finally,
it might be hypothetized that local hypoxia in inflammatory renal
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diseases (such as glomerulonephritis, hemolytic uremic syn-
drome) could stimulate endothelin release and thus aggravate the
underlying renal disease [19, 23].
A role of PDGF in the pathogenesis of diseases such as
pulmonary hypertension, renal allograft rejection, renal fibrosis in
proliferative glomerulonephritis and obstructive nephropathy,
and diabetic and hypertensive nephropathies has been promoted
[23-29]. As suggested for endothelin. local tissue hypoxia might be
present in different states of renal inflammation (such as rejection,
glomerulonephritis) and thereby stimulate secretion of PFGF,
causing proliferation of glomerular mesangial cells, progressive
glomeruloscierosis, and thus a further deterioration of renal
function. However, the results of the present study do not suggest
a prominent role for hypoxia-induced stimulation of PDGF
release. Stimulation of PDGF might be more relevant during
chronic than acute hypoxia [10].
It has been suggested that VEGF by means of its proliferative
effects on endothelial cells and its vasodilatory capacities might be
involved in vascularization of renal cell carcinomas and in restor-
ing blood flow and re-establishment of vascular integrity in
allograft rejection or vasculitis [30, 31]. Again our data, as with
PDGF, do not show a marked response of VEGF to acute
hypoxia, arguing against a critical role of acute hypoxia for
stimulation of VEGF gene expression in rejection and vasculitis.
A differentiation of the response of VEGF to ischemia from the
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Fig. 2. Renal gene expression of (A,) e,ythropoietin (EPO) and (B) VEGF 8% 02 0.1% CO Co (60 mg/kg)
duringhypoxia (8% 02), carbon monoxide treatment (0.1% CO), and cobalt
chloride treatment (Go). Values are given as a percentage of control rats. Fig. 3. Renal gene expression of (A) PDGF-A (E:), PDGF-B () and (B)
Data arc means SEM of 6 animals in each group. endothelin-1 (L,), endothelin-2 (, ET-1, ET-3) during hypoxia (8% 02),
carbon monoxide treatment (0.1% CO), and cobalt chloride treatment (Co).
Values are given as a percentage of control rats. Data are means SCM of
6 animals in each group. *P < 0.05 versus untreated animals.
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response to hypoxia has to be achieved in appropriate experimen-
tal models, studying short- and long-term effects of hypoxia and
tissue hypoperfusion.
There is evidence in cell culture studies that the gene expres-
sion of several growth factors/autoacoids such as erythropoietin,
endothelin, VEGF, and PDGF is regulated by oxygen tension
[1—7, 11—14]. Whether the oxygen regulation of these growth
factors follows the same principles as erythropoietin, the classic
hormone known to be regulated by oxygen in the sense of a
negative feedback is unknown. The results of the present study
argue against a common oxygen regulation shared by erythropoi-
etin on the one hand, and endothelins, PDGF, VEGF on the
other hand for the following reasons: (1.) The response to hypoxic
stimuli was either absent as with VEGF and PDGF or orders of
magnitude lower for endothelin-1 (1.6-fold) than for erythropoi-
etin (> 100-fold). (2.) The response to cobalt was absent for
endothelin-1 and VEGF in contrast to erythropoietin (and
PDGF-B). (3.) Renal ischemia in clipped kidneys induced an
increase of endothelin-1 gene expression, but did not change
erythropoietin gene expression [14].
An alternative explanation for differences between in vitro and
in viva PDGF or VEGF gene expression might be that the
respective gene expression in the organs of normoxic animals is
already rather high, whereas PDGF and VEGF mRNAs are hardly
detectable in normoxic cell cultures. Stimulation of, for example,
PDGF-B or VEGF, by cytokines using various signal transduction
pathways might cause the rather high constitutive gene expression in
vivo [32, 331. Therefore, PDGF and VEGF gene expression in the
organs of normoxic animals might be not or only to a minor extent
susceptible to further stimulation by hypoxic stimuli.
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